Atkinson Edward Morrow III, Chief Officer of Vertex Pharmaceuticals VRTX, has filed 0 purchases and 15 sales on the open market. Over the past 12 months that comes to a net sale of $3.6M. The latest trade was on 02/25.

AI

AI

Atkinson Edward Morrow III

EVP, Chief Technical Ops. Off

Company

Vertex Pharmaceuticals VRTX

First filing

23/02/13

Trades

49 trades

Buys / sales

0 / 15

12-month net buying

−$3.6M

Last trade

02/25

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	02/25	02/26	668 sh	$486.35	$324,881.8	−3.5%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	02/17–02/18	02/19	2,848 sh2 trades	$484.93avg.	$1,381,089.82	−12.1%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	02/11	02/12	1,751 sh	$460.43	$806,212.93	−7.4%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	25/11/17	25/11/19	2,500 sh	$434.58	$1,086,450	−12.9%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	25/02/27	25/02/28	2,650 sh	$475.34	$1,259,651	−12.0%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	25/02/25	25/02/26	1,767 sh	$480.95	$849,838.65	−6.7%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	25/02/11	25/02/12	1,747 sh	$459.83	$803,323.01	−7.0%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/06/12	24/06/13	7,288 sh	$478.00	$3,483,664	−31.3%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/26	24/02/27	883 sh	$425.70	$375,893.1	−5.2%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/21	24/02/23	1,201 sh	$421.77	$506,545.77	−6.1%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/20	24/02/21	801 sh	$420.79	$337,052.79	−3.9%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/12	24/02/13	913 sh	$420.24	$383,679.12	−3.8%
89 89bio	Open-market sale	23/06/01	23/06/05	6,250 sh	$17.91	$111,937.5	−100.0%
89 89bio	Open-market sale	23/03/01	23/03/03	10,000 sh	$13.60	$136,000	−100.0%